Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist.

Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist.
复制标题

DOI:
10.1021/jm1016285
复制
发表时间:
2011-04-14
影响因子:
7.3
通讯作者:
Tourwe, Dirk
Tourwe, Dirk
中科院分区:
医学1区
文献类型:
--
作者:
Ballet, Steven;Feytens, Debby;Buysse, Koen;Chung, Nga N.;Lemieux, Carole;Tumati, Suneeta;Keresztes, Attila;Van Duppen, Joost;Lai, Josephine;Varga, Eva;Porreca, Frank;Schiller, Peter W.;Broeck, Jozef Vanden;Tourwe, Dirk

文献摘要

参考文献

被引文献

相似文献

通过筛选构象受限的芳香族氨基酸作为新的NK1受体拮抗剂的碱基,发现了3个新的NK1受体拮抗剂,19个[Ac-Aba-Gly-NH-3‘,5’-(CF3)2-Bn],20个[Ac-Aba-Gly-NME-3‘,5’-(CF3)2-Bn]和23个[Ac-Tic-NME-3‘,5’-(CF3)2-Bn],它们能对抗NK1R的内源性配体P物质的兴奋作用。该系列中最活跃的NK1拮抗剂20[Ac-Aba-Gly-NME-3‘,5’-(CF3)2-Bn]被用来设计一种新型的、有效的嵌合阿片激动剂-NK1受体拮抗剂35[DMT-D-Arg-Aba-Gly-NME-3‘,5’-(CF3)2-Bn],它结合了已建立的DMT1-DALDA激动剂阿片药效团(H-DMT-D-Arg-Phe-Lys-NH2)和20,NK1R配体。嵌合化合物35的阿片成分,即DMT-D-Arg-Aba-Gly-NH2 36,也被证明是一种非常有效和平衡的μ和δ阿片受体激动剂,具有亚纳米分子结合和体外功能活性。
A screening of conformationally constrained aromatic amino acids as base cores for the preparation of new NK1 receptor antagonists resulted in the discovery of three new NK1 receptor antagonists, 19 [Ac-Aba-Gly-NH-3′,5′-(CF3)2-Bn], 20 [Ac-Aba-Gly-NMe-3′,5′-(CF3)2-Bn] and 23 [Ac-Tic-NMe-3′,5′-(CF3)2-Bn], which were able to counteract the agonist effect of substance P, the endogenous ligand of NK1R. The most active NK1 antagonist of the series, 20 [Ac-Aba-Gly-NMe-3′,5′-(CF3)2-Bn], was then used in the design of a novel, potent chimeric opioid agonist-NK1 receptor antagonist, 35 [Dmt-D-Arg-Aba-Gly-NMe-3′,5′-(CF3)2-Bn], which combines the N-terminus of the established Dmt1-DALDA agonist opioid pharmacophore (H-Dmt-D-Arg-Phe-Lys-NH2) and 20, the NK1R ligand. The opioid component of the chimeric compound 35, i.e. Dmt-D-Arg-Aba-Gly-NH2 36, also proved to be an extremely potent and balanced μ- and δ opioid receptor agonist with subnanomolar binding and in vitro functional activity.
DOI: 10.1016/j.bmcl.2008.11.051
发表时间: 2009-01-15
影响因子: 2.7
作者:
Ballet, Steven;Feytens, Debby;Balboni, Gianfranco
通讯作者: Balboni, Gianfranco
DOI: 10.1021/jm801205x
发表时间: 2009-01-08
影响因子: 7.3
作者:
Feytens, Debby;De Vlaeminck, Magali;Reubi, Jean Claude
通讯作者: Reubi, Jean Claude
DOI: 10.1016/j.regpep.2005.05.006
发表时间: 2005-11-15
影响因子: --
作者:
Janecka, A;Poels, J;Vanden Broeck, J
通讯作者: Vanden Broeck, J
DOI: 10.1111/j.1399-3011.2005.00291.x
发表时间: 2005-11-01
期刊: JOURNAL OF PEPTIDE RESEARCH
影响因子: --
作者:
Ballet, S;Frycia, A;Tourwé, D
通讯作者: Tourwé, D
DOI: 10.1002/psc.827
发表时间: 2007-03-01
影响因子: 2.1
作者:
Ballet, S.;De Wachter, R.;Tourwe, D.
通讯作者: Tourwe, D.